Cart
sales@molnova.com
Eupalinolide H
CAS No. 1402067-83-7
Eupalinolide H( —— )
Catalog No. M32257 CAS No. 1402067-83-7
Eupalinolide H, a sesquiterpene lactone, has the potential to be used as natural anti-inflammatory agent.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 410 | In Stock |
|
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEupalinolide H
-
NoteResearch use only, not for human use.
-
Brief DescriptionEupalinolide H, a sesquiterpene lactone, has the potential to be used as natural anti-inflammatory agent.
-
DescriptionEupalinolide H, a sesquiterpene lactone, has the potential to be used as natural anti-inflammatory agent.
-
In VitroEupalinolide H (2.5, 10, 40 μM) has significant inhibitory effects on IL-6 and TNF-α production in in RAW 264.7 cells.
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1402067-83-7
-
Formula Weight420.45
-
Molecular FormulaC22H28O8
-
Purity>98% (HPLC)
-
SolubilityDMSO, Pyridine, Methanol, Ethanol, etc.
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Nat Prod Res . 2019 Feb;33(4):477-485
molnova catalog
related products
-
SR10067
SR10067 is a potent, selective and brain penetrant agonist of Rev-Erbβ(IC50 = 160 nM) and Rev-Erbα(IC50 = 170 nM) with anxiolytic activity.
-
Roemerine
Roemerine is a potential active xanthine oxidase(XOD) inhibitor, XOD is a key enzyme in the pathogenesis of hyperuricemia and also a well-known target for the drug development to treat gout.
-
7-O -Methylaloesinol
7-O-Methylaloesinol is a chromone derivative. 7-O-Methylaloesinol shows significant inhibitory effects against TNFα-induced NF-κB transcriptional activity with an IC50 value of 29.07 μM.
